CG Oncology Director Leonard Post Exercises Options and Sells Shares at $70

CG Oncology, Inc. director Leonard E. Post filed a Form 4 disclosing significant stock transactions on June 24, 2026. Post exercised 5,000 stock options at $0.60 per share, acquiring 5,000 shares of common stock. On the same day, he sold all 5,000 of those shares at $70.00 per share through a pre-arranged Rule 10b5-1 trading plan. The options were fully vested and expire on July 8, 2028. Following these transactions, Post holds 106,077 stock options but no direct common stock shares. The sale was executed under a trading plan adopted on March 5, 2026, indicating a planned disposition rather than a sudden decision. These transactions represent a significant monetization of director compensation at a substantial premium over the exercise price.